Navigation Links
Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
Date:9/30/2009

CORAL GABLES, Fla., Sept. 30 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction. The Company's decision was made after, and based upon, an in-depth review of the results obtained from its 186-patient Phase II clinical trial evaluating the use of CPP-109 for the treatment of cocaine addiction (CPP-01004) and the top-line results obtained from its 57-patient proof-of-concept study evaluating the use of CPP-109 for the treatment of methamphetamine addiction (CPP-02001). Catalyst's decision to continue the development of the drug for both indications was supported by a panel of experts who recently met and agreed with the Company's conclusion that there was sufficient evidence of safety and efficacy to justify further development of CPP-109, based upon these trial data and previously published studies of vigabatrin to treat addiction.

Cocaine Trial Results

After post-hoc analyses of vigabatrin levels in urine samples collected during the study, Catalyst concluded that less than 40% of the trial subjects were medication compliant. As a result, the study was inadequately powered to test the protocol-specified efficacy hypotheses. On the basis of a comprehensive review of all study data, however, it was concluded that: (i) CPP-109 was safe and well tolerated; and (ii) while there were no statistically significant differences between active and placebo groups for the protocol-specified primary and secondary efficacy endpoints, there were positive and consistent data trends observed in favor of CPP-109 across measures of cocaine abstinence, reduction in use, and reduction in use days.

Despite the limitations resulting from poor medic
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
2. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
3. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
6. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
7. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
8. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
9. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
10. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Md., June 01, 2007 /PRNewswire-FirstCall/ --,EntreMed, Inc. ... the treatment of cancer and inflammatory diseases,announced ... Aurora,kinase - angiogenesis inhibitor, ENMD-981693. The data ... EntreMed,scientists at the 2nd Protein Kinases in ...
... Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. ... ongoing clinical,studies of SNS-595 and SNS-032 at the ... held June 7-10, 2007 in Vienna,Austria. , Presentations ... 1 clinical trial of SNS-595 in acute leukemias, ...
Cached Medicine Technology:EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 2EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 3Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3
(Date:7/11/2014)... 11, 2014 Shoulder instability is a ... return to play has not been regularly determined following ... Society for Sports Medicine’s ( AOSSM ) Annual Meeting ... approximately 90 percent no matter what the stabilization procedure ... rate of return to play following shoulder stabilization surgery. ...
(Date:7/11/2014)... occur more than 200,000 times a year, but the ... may determine how long you stay in the game, ... Meeting of the American Orthopaedic Society of Sports Medicine ... in a young athletic population, allografts (tissue harvested from ... harvested from the patient)," said Craig R. Bottoni, MD, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Woodland Hills ... founder of the Anacapa Dental Art Institute in Woodland Hills ... Biocare World Symposium in Marina Del Rey, Calif. , ... master class on the permanent teeth in one day dental ... teeth in one day was developed 15 years ago, Dr. ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The World Cup ... according to recent reports , many star soccer players left ... in the media to American football when it comes to ... risk is always there. While none of the soccer superstars ... possibility remains. Beverly Hills spine surgeon Dr. Gravori reveals some ...
(Date:7/11/2014)... 2014 On Tuesday, July 9, Eric ... VA office joined CBS affiliate WUSA’s Andrea Roane ... the audience about the number of ways Shady Grove ... motherhood possible for women after they undergo cancer ... patients in the developing field known as oncofertility which ...
Breaking Medicine News(10 mins):Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL reconstructions may last longer with autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:As World Cup Comes to an End, Injuries are Star of the Show 2Health News:As World Cup Comes to an End, Injuries are Star of the Show 3Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 2Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 3Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 4
... The University of Houston (UH) will soon open its doors ... a new joint venture between the UH Graduate College of ... Cancer Center Division of Cancer Prevention and Population Sciences. CHEER ... the newly opened center at UH GCSW. CHEER ...
... blood vitamin D levels, there,s uncertainty about where the ... threshold amount has become controversial as several scientific societies ... University of Washington researchers conducted an observational study. They ... circulating in the blood to lower the risk of ...
... , TUESDAY, May 1 (HealthDay News) -- Children with ... hospitalized than children without arthritis, a new study says. ... higher infection risk among kids with arthritis, other arthritis ... inhibitors -- were not. Researchers analyzed Medicaid ...
... can have as much effect on the teens, substance ... "Among friendship groups with ,good parents, there,s a ... aware of your whereabouts, and your friends, parents are ... you are less likely to use substances," said Michael ...
... announced today the inaugural class of its Presidential ... early career researchers with financial support to attend ... exclusive networking and mentoring opportunities with AcademyHealth leadership ... "The presidential scholarships are an opportunity for ...
... 1, 2012 Scientists at Joslin Diabetes Center have identified ... rapamycin) protein kinase, a critical regulator of cell growth which ... finding not only illuminates the physiology of aging but could ... conditions, such as cancer, type 2 diabetes, and neurodegeneration. ...
Cached Medicine News:Health News:University of Houston Graduate College of Social Work announces partnership with MD Anderson 2Health News:Researchers determine vitamin D blood level for reducing major medical risks in older adults 2Health News:Arthritis in Children Linked to Infections 2Health News:It takes a village to keep teens substance free 2Health News:First recipients of AcademyHealth's Presidential Scholarship announced 2Health News:Joslin scientists identify important mechanism that affects the aging process 2Health News:Joslin scientists identify important mechanism that affects the aging process 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: